The new role of antiretrovirals in combination HIV prevention: A mathematical modelling analysis

AIDS

Volumn 27, Issue 3, 2013, Pages 447-458

  Cremin, Ide ^a   Alsallaq, Ramzi ^b   Dybul, Mark ^c,d   Piot, Peter ^e   Garnett, Geoffrey ^f   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NEW YORK UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^d George W Bush Institute   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

antiretroviral therapy; combination prevention; HIV; mathematical models; pre exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CIRCUMCISION; COHORT ANALYSIS; CONDOM; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; DRUG EXPOSURE; EPIDEMIC; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MALE; MATHEMATICAL MODEL; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUALITY OF LIFE; SOUTH AFRICA;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CIRCUMCISION, MALE; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, THEORETICAL; SOUTH AFRICA;

EID: 84872307462     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ca2dd     Document Type: Article

References (66)

1. UNAIDS. 2012. Together we will end AIDS. http://www.unaid-s.org/en/ resources/campaigns/togetherwewillendaids/unaidsre-port/[Accessed 5 December 2012].
2. Over M. Achieving an AIDS transition. Preventing infections to sustain treatment. Washington, DC: Center for Global Development; 2011.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
4. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
5. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
6. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
7. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
8. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
9. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
10. The Economist. The end of AIDS? The 30 years war. http://www.economist. com/node/18772276; 2011. [Accessed 2 June 2011].
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
12. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
13. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
14. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
15. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
16. Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. http://www.mtnstopshiv.org/node/3619 [Accessed 5 December 2012].
17. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. In: 2012 Conference on Retroviruses and Opportunistic Infections; 2012 http://www.retroconference.org/2012b/Abstracts/45406. htm.
18. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011; 378:e23-e25.
19. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Preexpo-sure prophylaxis for HIV prevention: how to predict success. Lancet 2012; 379:2409-2411.
20. Celum C, Baeten JM. Tenofovir-based preexposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 2012; 25:51-57.
21. Wandel S, Egger M, Rangsin R, Nelson KE, Costello C, Lewden C, et al. Duration from seroconversion to eligibility for anti-retroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008; 84 (Suppl 1):i31-i36.
22. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
23. Mahy M, Lewden C, Brinkhof MW, Dabis F, Tassie JM, Souteyr-and Y, et al. Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretro-viral therapy. Sex Transm Infect 2010; 86 (Suppl 2):ii28-34.
24. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
25. Statistics South Africa. Mid-year population estimates. http://www.statssa.gov.za/publications/statspastfuture.-asp?PPN=P0302&SCH= 4696 [Accessed 5 December 2012].
26. WHO. Global Health Observatory Data Repository. South Africa life tables. Available at: http://www.who.int/gho/coun-tries/zaf/en/[Accessed 5 December 2012].
27. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008: a turning tide among teenagers? Cape Town: HSRC Press; 2009.
28. Barnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, Viljoen J, et al. HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One 2008; 3:e3640.
29. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML. High HIV incidencein a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS 2008; 22:139-144.
30. The Epidemiology Unit of KwaZulu-Natal Department of Health. KwaZulu-Natal Epidemiology Bulletin. Weekly Monitoring System of the Antiretroviral Therapy for HIV/AIDS in KZN. http://www.kznhealth.gov.za/ epibulletin10.pdf. [Accessed 5 December 2012].
31. Centers for Disease Control and Prevention. TDF2 study of Pre-Exposure Prophylaxis (PrEP) among heterosexual men and women in Botswana. http://www.cdc.gov/nchhstp/newsroom/docs/PrEP-Heterosexuals-Factsheet.doc. [Accessed 5 December 2012].
32. Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 2011; 8:e1001055.
33. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011; 25:1753-1760.
34. Vella V, Govender T, Dlamini SS, Moodley I, David V, Taylor M, et al. Cost-effectiveness of staff and workload profiles in retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. AIDS Care 2011; 23:1146-1153.
35. Blecher M. Health and HIV Funding. Budget Monitoring Forum. National Treasury, Republic of South Africa. http://sectio-n27.org.za.dedi47.cpt1.host-h. net/2009/08/21/bemf/. [Accessed 5 December 2012].
36. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of preexposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646.
37. Bill & Melinda Gates foundation. Oral PrEP in South Africa. Bottom-up cost model. Spreadsheet available at: http://www.gatesfoundation.org/ grantseeker/Documents/program-cost-model-rsa.xls. [Accessed 5 December 2012].
38. USNational Institutes of Health. Strategic TimingofAntiretroviral Treatment (START). Information available at: http://clinicaltrials.-gov/ct2/ show/NCT00867048. [Accessed 5 December 2012].
39. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Section E-1. http://www.aidsinfo.nih.gov/Con-tentFiles/AdultandAdolescentGL.pdf. [Accessed 5 December 2012].
40. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapyorimmunotherapyto control the spread of HIV-1. Nature 1991; 350:356-359.
41. Garnett GP, Bartley L, Grassly NC, Anderson RM. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med 2002; 8:651-654.
42. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
43. Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epide-miological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011; 58:207-210.
44. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of preexposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504-1513.
45. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007; 2:e875.
46. van de Vijver DA, Derdelinckx I, Boucher CA. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009; 199:1310-1317.
47. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of preexposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008; 3:e2077.
48. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829-1839.
49. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806-815.
50. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, et al. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med 2012; 9:e1001323.
51. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031-2041.
52. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011; 8:62-72.
53. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002: CD003255.
54. Chimbiri AM. The condom is an 'intruder' in marriage: evidence from rural Malawi. Soc Sci Med 2007; 64:1102-1115.
55. Johnson LF, Hallett TB, Rehle TM, Dorrington RE. The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface 2012; 9:1544-1554.
56. UNAIDS. Report on the Global AIDS epidemic 2010. Geneva: UNAIDS; 2010.
57. Njeuhmeli E, Forsythe S, Reed J, Opuni M, Bollinger L, Heard N, et al. Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med 2011; 8:e1001132.
58. WHO, UNAIDS. Joint Strategic Action Framework to Accelerate the Scale-Up of Voluntary Medical Male Circumcision for HIV Prevention in Eastern and Southern Africa 2012-2016. Available at: http://whqlibdoc.who.int/unaids/2011/ JC2251E- eng.pdf. [Accessed 5 December 2012].
59. WHO, UNAIDS. WHO and UNAIDS announce recommendations from expert meeting on male circumcision for HIV prevention. http://data.unaids.org/pub/ pressrelease/2007/20070328- pr-mc-recommendations-en.pdf. [Accessed 5 December 2012].
60. UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention. Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med 2009; 6:e1000109.
61. Vermund SH. Modeling interventions to assess HIV epidemic impact in Africa. J Acquir Immune Defic Syndr 2011; 58:121-124.
62. WHO, UNAIDS, UNICEF. Global HIV/AIDS Response. Epidemic update and health sector progress towards universal access. Progress Report. Geneva: WHO; 2011.
63. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011; 25:2177-2181.
64. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science 2011; 333:42-43.
65. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378:269-278.
66. Cohen J. HIV prevention. Halting HIV/AIDS epidemics. Science 2011; 334:1338-1340.